• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于采用 4D-CT 强度调制放射治疗的局部晚期非小细胞肺癌,是否需要临床靶区。

Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.

机构信息

Department of Oncology, The Third Xiangya Hospital of Central South University, Central South University, Changsha, China.

Department of Oncology, Xiangxi Autonomous Prefecture People's Hospital, Ji Shou University, Jishou, China.

出版信息

BMC Cancer. 2024 Sep 27;24(1):1198. doi: 10.1186/s12885-024-12979-z.

DOI:10.1186/s12885-024-12979-z
PMID:39334061
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11438206/
Abstract

BACKGROUND

A dosimetric evaluation is still lacking in terms of clinical target volume (CTV) omission in stage III patients treated with 4D-CT Intensity-Modulated Radiation Therapy (IMRT).

METHODS

49 stage III NSCLC patients received 4D-CT IMRT were reviewed. Target volumes and organs at risk (OARs) were re-delineated. Four IMRT plans were conducted retrospectively to deliver different prescribed dose (74 Gy-60 Gy), and with or without CTV implementation. Dose and volume histogram (DVH) parameters were collected and compared.

RESULTS

In the PTV-g 60 Gy plan (PTV-g refers to the PTV generated from the internal gross tumor volume), only 5 of 49 patients had the isodose ≥ 50 Gy line covering at least 95% of the PTV-c (PTV-c refers to the PTV generated from the internal CTV) volume. When the prescribed dose was elevated to 74 Gy to the PTV-g, 33 of 49 patients could have the isodose ≥ 50 Gy line covering at least 95% of the PTV-c volume. In terms of OARs protection, the SIB-IMRT plan showed the lowest value of V5, V20, and mean dose of lung, had the lowest V55 of esophagus, and the lowest estimated radiation doses to immune cells (EDIC). The V20, V30, and mean dose of heart was lower in the simultaneous integrated boost (SIB) IMRT (SIB-IMRT) plan than that of the PTV-c 60 Gy plan.

CONCLUSIONS

CTV omission was not suitable for stage III patients when the prescribed dose to PTV-g was 60 Gy in the era of 4D-CT IMRT. CTV omission plus high dose to PTV-g (74 Gy for example) warranted further exploration. The SIB-IMRT plan had the best protection to normal tissue including lymphocytes, and might be the optimal choice.

摘要

背景

在采用四维 CT 调强放疗(IMRT)治疗 III 期患者时,临床靶区(CTV)遗漏的剂量学评估仍存在不足。

方法

回顾性分析 49 例接受 4D-CT-IMRT 治疗的 III 期非小细胞肺癌患者。重新勾画靶区和危及器官(OARs)。回顾性地进行了 4 个 IMRT 计划,以提供不同的规定剂量(74Gy-60Gy),并分别实施和不实施 CTV。收集并比较剂量和体积直方图(DVH)参数。

结果

在 PTV-g 60Gy 计划(PTV-g 是指从内部大体肿瘤体积生成的 PTV)中,只有 5 例患者的等剂量线(isodose line)≥50Gy 线覆盖了 PTV-c(PTV-c 是指从内部 CTV 生成的 PTV)体积的至少 95%。当将规定剂量提高到 PTV-g 的 74Gy 时,49 例患者中有 33 例患者的等剂量线≥50Gy 线覆盖了 PTV-c 体积的至少 95%。在保护 OARs 方面,SIB-IMRT 计划的 V5、V20 和肺的平均剂量最低,食管的 V55 最低,免疫细胞(EDIC)的估计辐射剂量最低。与 PTV-c 60Gy 计划相比,同步整合推量(SIB)IMRT(SIB-IMRT)计划的 V20、V30 和心脏的平均剂量较低。

结论

在 4D-CT-IMRT 时代,当 PTV-g 的规定剂量为 60Gy 时,III 期患者不适合进行 CTV 遗漏。CTV 遗漏加高剂量至 PTV-g(例如 74Gy)需要进一步探索。SIB-IMRT 计划对包括淋巴细胞在内的正常组织具有最佳保护作用,可能是最佳选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5865/11438206/989df2065c6a/12885_2024_12979_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5865/11438206/fe6c049ac80f/12885_2024_12979_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5865/11438206/03bfcda7a792/12885_2024_12979_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5865/11438206/989df2065c6a/12885_2024_12979_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5865/11438206/fe6c049ac80f/12885_2024_12979_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5865/11438206/03bfcda7a792/12885_2024_12979_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5865/11438206/989df2065c6a/12885_2024_12979_Fig1_HTML.jpg

相似文献

1
Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy.对于采用 4D-CT 强度调制放射治疗的局部晚期非小细胞肺癌,是否需要临床靶区。
BMC Cancer. 2024 Sep 27;24(1):1198. doi: 10.1186/s12885-024-12979-z.
2
Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? -a dosimetric evaluation of three different treatment plans.调强放射治疗局部晚期非小细胞肺癌时临床靶区(CTV)是否必要?——三种不同治疗计划的剂量学评估
J Thorac Dis. 2017 Dec;9(12):5194-5202. doi: 10.21037/jtd.2017.10.147.
3
Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.评估蒙特卡罗算法在接受立体定向体部放射治疗的周围型肺癌患者中符合 RTOG 0915 剂量学标准的应用。
J Appl Clin Med Phys. 2016 May 8;17(3):277-293. doi: 10.1120/jacmp.v17i3.6077.
4
Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer.肺癌调强质子治疗中4D与3D稳健优化的探索性研究
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):523-533. doi: 10.1016/j.ijrobp.2015.11.002. Epub 2015 Nov 10.
5
Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study.同步整合推量强度调控放射治疗与常规强度调控放射治疗局部晚期非小细胞肺癌的疗效与安全性比较:一项回顾性研究。
Radiat Oncol. 2019 Jun 13;14(1):106. doi: 10.1186/s13014-019-1259-3.
6
Dosimetric comparison between helical tomotherapy and intensity-modulated radiation therapy plans for non-small cell lung cancer.螺旋断层放疗与调强放疗计划治疗非小细胞肺癌的剂量学比较。
Chin Med J (Engl). 2011 Jun;124(11):1667-71.
7
Volumetric-modulated arc therapy for the treatment of a large planning target volume in thoracic esophageal cancer.容积旋转调强弧形治疗技术在胸段食管癌大靶区中的应用。
J Appl Clin Med Phys. 2013 May 6;14(3):4269. doi: 10.1120/jacmp.v14i3.4269.
8
A potential to reduce pulmonary toxicity: the use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer.降低肺部毒性的潜力:在非小细胞肺癌放疗中使用灌注单光子发射计算机断层扫描(SPECT)联合调强放射治疗(IMRT)进行功能性肺避让。
Radiother Oncol. 2007 May;83(2):156-62. doi: 10.1016/j.radonc.2007.04.005. Epub 2007 May 9.
9
Technical Note: Dosimetric evaluation of Monte Carlo algorithm in iPlan for stereotactic ablative body radiotherapy (SABR) for lung cancer patients using RTOG 0813 parameters.技术说明:使用RTOG 0813参数,在iPlan中对肺癌患者立体定向消融体部放疗(SABR)的蒙特卡罗算法进行剂量学评估。
J Appl Clin Med Phys. 2015 Jan 8;16(1):5058. doi: 10.1120/jacmp.v16i1.5058.
10
A novel four-dimensional radiotherapy planning strategy from a tumor-tracking beam's eye view.一种从肿瘤跟踪视野的角度出发的新型四维放射治疗计划策略。
Phys Med Biol. 2012 Nov 21;57(22):7579-98. doi: 10.1088/0031-9155/57/22/7579. Epub 2012 Oct 26.

本文引用的文献

1
Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy.癌症治疗相关心脏毒性的细胞间途径及其治疗意义:放射治疗范例。
Pharmacol Ther. 2024 Aug;260:108670. doi: 10.1016/j.pharmthera.2024.108670. Epub 2024 May 31.
2
Adaptive Radiotherapy: Next-Generation Radiotherapy.自适应放疗:下一代放疗技术
Cancers (Basel). 2024 Mar 19;16(6):1206. doi: 10.3390/cancers16061206.
3
Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy.
同步放化疗治疗的非小细胞肺癌患者,治疗过程中出现淋巴细胞减少与治疗结局和巩固性免疫治疗疗效相关。
Radiother Oncol. 2023 Dec;189:109934. doi: 10.1016/j.radonc.2023.109934. Epub 2023 Sep 30.
4
Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.同步放化疗治疗局部晚期非小细胞肺癌患者采用免疫治疗巩固前后的肺炎发生率
Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1445-1454. doi: 10.1016/j.ijrobp.2023.08.039. Epub 2023 Aug 22.
5
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.不可切除 III 期非小细胞肺癌患者在放化疗后接受度伐利尤单抗治疗的特点和真实世界无进展生存:PACIFIC-R 研究结果。
J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25.
6
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era.度伐利尤单抗时代不可切除或 III 期非小细胞肺癌中免疫细胞的辐射剂量影响。
Radiother Oncol. 2022 Sep;174:133-140. doi: 10.1016/j.radonc.2022.07.015. Epub 2022 Jul 20.
7
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.舒格利单抗联合同步或序贯放化疗对比安慰剂用于中国局部晚期、不可切除、III 期非小细胞肺癌患者的 GEMSTONE-301 研究:一项随机、双盲、多中心、III 期临床研究的期中分析结果
Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14.
8
Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617.III期非小细胞肺癌患者中,免疫细胞接受更高辐射剂量与更差的肿瘤控制及总生存期相关:RTOG0617的二次分析
Cancers (Basel). 2021 Dec 8;13(24):6193. doi: 10.3390/cancers13246193.
9
Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.接受放化疗及免疫检查点抑制剂治疗的非小细胞肺癌患者放射性肺炎:一项回顾性研究
Radiat Oncol. 2021 Dec 4;16(1):231. doi: 10.1186/s13014-021-01930-2.
10
Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC.有效剂量对免疫细胞(EDIC)的影响与局限期小细胞肺癌中淋巴细胞最低点和存活的关系。
Radiother Oncol. 2021 Sep;162:26-33. doi: 10.1016/j.radonc.2021.06.020. Epub 2021 Jun 15.